Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization

Timothy W. Olsen; Nancy M. Benegas; Andrea C. Joplin; Tony Evangelista; Elizabeth A. Mindrup; Edward J. Holland

doi:10.1001/archopht.1994.01090230085026

Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization

Timothy W. Olsen, Nancy M. Benegas, Andrea C. Joplin, Tony Evangelista, Elizabeth A. Mindrup, Edward J. Holland

Ophthalmology

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

Objective: To investigate the immunosuppresive effect of rapamycin in prolonging allograft survival in the rat model of orthotopic allogeneic penetrating keratoplasty. Design: Thirty inbred Lewis rats received corneal allografts from Brown Norway donors. Animals were divided into two rapamycin treatment groups and one allogeneic control group. Results: By the second week after surgery, all of the control animals had experienced allograft failure due to allograft rejection. However, allografts in seven of 10 animals in the low-dose treatment group and allografts in seven of nine animals in the high-dose treatment group remained clear. In addition, corneal neovascularization was markedly reduced in the treated animals. Conclusion: The systemic administration of rapamycin prolongs corneal allograft survival and significantly inhibits the neovascular component of rejection in the rat model of orthotopic allogeneic penetrating keratoplasty.

Original language	English (US)
Pages (from-to)	1471-1475
Number of pages	5
Journal	Archives of ophthalmology
Volume	112
Issue number	11
DOIs	https://doi.org/10.1001/archopht.1994.01090230085026
State	Published - Nov 1994

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1001/archopht.1994.01090230085026

Cite this

@article{dd18cec0077945f69d1318cd36de9867,

title = "Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization",

abstract = "Objective: To investigate the immunosuppresive effect of rapamycin in prolonging allograft survival in the rat model of orthotopic allogeneic penetrating keratoplasty. Design: Thirty inbred Lewis rats received corneal allografts from Brown Norway donors. Animals were divided into two rapamycin treatment groups and one allogeneic control group. Results: By the second week after surgery, all of the control animals had experienced allograft failure due to allograft rejection. However, allografts in seven of 10 animals in the low-dose treatment group and allografts in seven of nine animals in the high-dose treatment group remained clear. In addition, corneal neovascularization was markedly reduced in the treated animals. Conclusion: The systemic administration of rapamycin prolongs corneal allograft survival and significantly inhibits the neovascular component of rejection in the rat model of orthotopic allogeneic penetrating keratoplasty.",

author = "Olsen, {Timothy W.} and Benegas, {Nancy M.} and Joplin, {Andrea C.} and Tony Evangelista and Mindrup, {Elizabeth A.} and Holland, {Edward J.}",

year = "1994",

month = nov,

doi = "10.1001/archopht.1994.01090230085026",

language = "English (US)",

volume = "112",

pages = "1471--1475",

journal = "Archives of ophthalmology",

issn = "0003-9950",

publisher = "American Medical Association",

number = "11",

}

TY - JOUR

T1 - Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization

AU - Olsen, Timothy W.

AU - Benegas, Nancy M.

AU - Joplin, Andrea C.

AU - Evangelista, Tony

AU - Mindrup, Elizabeth A.

AU - Holland, Edward J.

PY - 1994/11

Y1 - 1994/11

N2 - Objective: To investigate the immunosuppresive effect of rapamycin in prolonging allograft survival in the rat model of orthotopic allogeneic penetrating keratoplasty. Design: Thirty inbred Lewis rats received corneal allografts from Brown Norway donors. Animals were divided into two rapamycin treatment groups and one allogeneic control group. Results: By the second week after surgery, all of the control animals had experienced allograft failure due to allograft rejection. However, allografts in seven of 10 animals in the low-dose treatment group and allografts in seven of nine animals in the high-dose treatment group remained clear. In addition, corneal neovascularization was markedly reduced in the treated animals. Conclusion: The systemic administration of rapamycin prolongs corneal allograft survival and significantly inhibits the neovascular component of rejection in the rat model of orthotopic allogeneic penetrating keratoplasty.

AB - Objective: To investigate the immunosuppresive effect of rapamycin in prolonging allograft survival in the rat model of orthotopic allogeneic penetrating keratoplasty. Design: Thirty inbred Lewis rats received corneal allografts from Brown Norway donors. Animals were divided into two rapamycin treatment groups and one allogeneic control group. Results: By the second week after surgery, all of the control animals had experienced allograft failure due to allograft rejection. However, allografts in seven of 10 animals in the low-dose treatment group and allografts in seven of nine animals in the high-dose treatment group remained clear. In addition, corneal neovascularization was markedly reduced in the treated animals. Conclusion: The systemic administration of rapamycin prolongs corneal allograft survival and significantly inhibits the neovascular component of rejection in the rat model of orthotopic allogeneic penetrating keratoplasty.

UR - http://www.scopus.com/inward/record.url?scp=0028144044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028144044&partnerID=8YFLogxK

U2 - 10.1001/archopht.1994.01090230085026

DO - 10.1001/archopht.1994.01090230085026

M3 - Article

C2 - 7980138

AN - SCOPUS:0028144044

SN - 0003-9950

VL - 112

SP - 1471

EP - 1475

JO - Archives of ophthalmology

JF - Archives of ophthalmology

IS - 11

ER -

Rapamycin Inhibits Corneal Allograft Rejection and Neovascularization

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this